NEWS
SSRP Institute
Sep 14, 2026

In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD

HEADLINE SCIENCE

[Sept 14, 2026] - On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the first dual GIP/GLP-1 receptor agonist with an FDA-approved cardiovascular risk-reduction indication.

The approval is supported by results from the SURPASS-CVOT trial, which enrolled more than 13,000 adults across 30 countries and followed participants for more than four years. Tirzepatide demonstrated noninferiority to the GLP-1 receptor agonist dulaglutide (Trulicity), with an 8% lower rate of major cardiovascular events. Importantly, superiority to dulaglutide for MACE was not established. The expanded indication further shifts the clinical role of incretin-based therapies beyond glucose control and weight management toward broader cardiometabolic risk reduction.

Read the Full Announcement

For further details, please refer to: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s044%2C215866Orig1s045ltr.pdf

For future updates like this, education, training, and support, explore what the SSRP Community has to offer.

RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
VIDEO
Cellular Medicine Mondays
Nov 16, 2026
Ep. 114 Anti-Aging Mini Mastermind Part 4
Preview only
Journal Club – Episode 114

In Part 4 of the Anti-Aging Mini Mastermind, Dr. Seeds explores how NAD synthesis, mitochondrial function, and cellular signaling influence immune function, inflammation, and aging through the lens of cellular medicine.

Preview Only — Become a member for full access
SSRP Institute Nov 12, 2026
FDA Requires New Safety Warnings for GLP-1 Receptor Agonists Due to Potential Vision Risk
BREAKING NEWS [NOVEMBER 12, 2026] – On November 9, the U.S. Food and Drug Administration (FDA) announced new safety labeling requirements for glucagon-like peptide-1 receptor agonists (GLP-1 RAs), citing a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare but serious condition that can cause sudden, painless vision loss, sometimes permanently. The […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Nov 9, 2026
Ep. 113 - Dr. Seeds' Office Hours
Preview only
Dr. Seeds’ Office Hours – Episode 113

1. Dr. Seeds explores the clinical priorities in a 50-year-old female kidney transplant recipient with lupus, chronic steroid use, IBS, fatigue, and reported low morning glucose, focusing on metabolic function, gut health, and preserving immune tolerance. [0:47]

Preview Only — Become a member for full access
Promoitalia Nov 5, 2026
SSRP Institute Welcomes Promoitalia as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [November 5, 2026] — The SSRP Institute announces that Promoitalia has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Promoitalia is an Italian aesthetic medicine company that develops professional technologies, methodologies, and consumable products for regenerative aesthetics and skin health. Its work combines professional […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Nov 2, 2026
Ep. 112 - Peptide Therapy Gets a Smarter Upgrade
Preview only
Dissecting Protocols – Episode 112

Peptide Therapy Gets a Smarter Upgrade

Dr. Seeds addresses the often-overlooked challenges of peptide purity, patient adherence, and administration. He also shares the journey behind the Redox Smart Pen, highlighting years of collaboration with scientists, physicians, and formulators to help raise the standard for peptide therapy and advance the future of cellular medicine.

Preview Only — Become a member for full access
SSRP Institute Oct 29, 2026
Dr. Seeds and Medivive Announce the Redox Smart Pen: A Novel Technology for Precise Peptide Administration
BREAKING NEWS WILLOUGHBY, Ohio [October 29, 2026] — Dr. Seeds and Medivive announce the launch of the Redox Smart Pen, an innovative pre-filled autoinjector peptide delivery system designed to improve precision and consistency in physician-directed peptide protocols. Importantly, the Redox Smart Pen was developed through a proprietary methodology focused on uniform potency, accuracy of administration, […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Oct 26, 2026
Ep. 111 - Can BPC-157 & HBOT Prevent Amputation?
Preview only
Dissecting Protocols – Episode 111

Can BPC-157 & HBOT Prevent Amputation?

Dr. Seeds explores the potential and limitations of these investigational approaches, emphasizing the importance of blood flow, patient phenotyping, and cellular function in limb salvage. (Question Link)

Preview Only — Become a member for full access
PharmaNutra Oct 22, 2026
SSRP Institute Welcomes PharmaNutra as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [October 22, 2026] — The SSRP Institute announces that PharmaNutra has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Founded in Italy in 2003, PharmaNutra is a pharmaceutical and nutraceutical company focused on the research, development, and production of nutritional supplements and medical devices. […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Oct 19, 2026
Ep. 110 - The Macrophage Mystery: Decoding Aging
Preview only
Rabbit Holes – Episode 110

The Macrophage Mystery: Decoding Aging

In Part 3 of our Anti-Aging Mini Mastermind, Dr. Seeds explores how aging alters PGE2/EP2 signaling, influencing macrophage metabolism, immune function, and inflammation, and examines potential therapeutic implications.
Articles referenced: (2026 Article) (2021 Article)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Oct 12, 2026
Ep. 109 - Anti-Aging Mini Mastermind Part 2
Preview only
Journal Club – Episode 109

Anti-Aging Mini Mastermind Part 2

In Part 2 of our Anti-Aging Mini Mastermind series, Dr. Seeds explores how PGE2 signaling and cellular metabolism influence inflammation, cognitive function, and aging, connecting foundational research to emerging discoveries in immunometabolism.  (2026 Article) (2021 Article)

Preview Only — Become a member for full access

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.